Finance

Lists
RPGLIFE:NSE
RPG Life Sciences Ltd
₹2 569,00
-1,31%
(-34,20) 1D
13 Nov., 15:30:02 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for RPGLIFE...
Open
₹2 603,20
High
₹2 616,40
Low
₹2 532,00
Mkt. cap
42,59 mjd
Avg. vol.
27,55 k
Volume
5,68 k
Dividend
0,93%
Quarterly dividend
₹6,00
Ex-dividend date
09 Jul. 2026
P/E ratio
38,27
52-wk high
₹3 127,80
52-wk low
₹1 733,00
EPS
₹67,13
Shares outstanding
16,54 m
No. of employees
1 k
Open
₹2 603,20
High
₹2 616,40
Low
₹2 532,00
Mkt. cap
42,59 mjd
Avg. vol.
27,55 k
Volume
5,68 k
Dividend
0,93%
Quarterly dividend
₹6,00
Ex-dividend date
09 Jul. 2026
P/E ratio
38,27
52-wk high
₹3 127,80
52-wk low
₹1 733,00
EPS
₹67,13
Shares outstanding
16,54 m
No. of employees
1 k
News stories
From web sources and news partners
Profile
RPG Life Sciences is an Indian pharmaceutical company. Formerly known as Searle Ltd, RPG Life Sciences is part of RPG Enterprises. It has its corporate office in RPG House in Worli, Mumbai. Its three major activities are the manufacturing and marketing of bulk drugs, also known as active pharmaceutical ingredients; pharmaceutical formulation; and fermentation and biotechnology. RPGLS is present in the domestic as well as the international market. It exports its products primarily to Europe, Latin America, Australia and South East Asian countries. Wikipedia
About RPG Life Sciences Ltd
CEO-
Employees1,37 k
Founded1993
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Last report
30 Okt. 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
2,12 mjd / -
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
1,80 mjd
1,77 mjd
1,96 mjd
2,12 mjd
Cost of goods sold
649,00 m
661,00 m
681,50 m
721,40 m
Cost of revenue
649,00 m
661,00 m
681,50 m
721,40 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
353,20 m
570,90 m
377,60 m
440,90 m
Operating expense
807,50 m
835,00 m
901,50 m
1,06 mjd
Total operating expenses
1,46 mjd
1,50 mjd
1,58 mjd
1,78 mjd
Operating income
343,80 m
273,30 m
373,90 m
336,20 m
Other non operating income
34,10 m
-101,90 m
47,00 m
42,60 m
EBT including unusual items
291,20 m
402,00 m
414,60 m
370,40 m
EBT excluding unusual items
375,40 m
277,30 m
414,60 m
370,40 m
Income tax expense
69,90 m
103,00 m
107,00 m
88,20 m
Effective tax rate
24,00%
25,62%
25,81%
23,81%
Other operating expenses
400,50 m
206,70 m
464,90 m
549,90 m
Net income
221,30 m
299,00 m
307,60 m
266,00 m
Net profit margin
12,29%
16,90%
15,72%
12,57%
Earnings per share
-
-
-
-
Interest and investment income
-
96,70 m
-
-
Interest expense
-2,50 m
-3,90 m
-6,30 m
-8,40 m
Net interest expenses
-2,50 m
92,80 m
-6,30 m
-8,40 m
Depreciation and amortization charges
53,80 m
57,40 m
59,00 m
68,00 m
EBITDA
395,75 m
325,80 m
426,40 m
399,70 m
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme